SAB Biotherapeutics has developed novel SAB-176, an investigational drug for post-exposure prophylaxis of influenza A and B in high-risk patients, including those with resistant strains of the virus.
SAB-176 is a highly effective immunotherapy based on the fundamentals of the innate immune response to neutralise influenza A and B viruses by generating endogenous antibodies that bind to multiple epitopes.
The treatment is produced on patented DiversitAb™ platform, which allows for the first time rapid and large-scale production of highly potent fully human polyclonal IgG antibodies without the requirement of human donors.
Several clinical and pre-clinical studies such as Phase 1 trial in healthy volunteers and a Phase 2a challenge study that ended last year have shown that SAB-176 provides broad antibody protection against multiple strains of this rapidly evolving virus.
Influenza continues to cause serious health problems in the United States and around the world. SAB-176 consisting of multi-epitope targeting method has a clear difference compared to monoclonal antibodies (mAb) and can maintain its effectiveness against viral mutations in preventing or reducing the risk of treatment resistance influenza strains.
U.S. Food and Drug Administration (FDA) grants Breakthrough Therapy Designation (BTD) to SAB-176, an investigational therapeutic for the treatment of post-exposure prophylaxis of Type A and Type B influenza.
